2Seemungal TA,Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2000,161 (5) : 1608-1613.
3Stockley RA,O' Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD[J]. Chest, 2000,117(6) : 1638-1645.
4Adams SG, Melo J, Luther M, et al Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD[J]. Chest,2000,117(5) :1345-1352.
5Dewan NA,Rafique S, Kanwar B, et al. Acute exacerbation of COPD:factors associated with poor treatment outcome [J]. Chest,2000,117(3) :662-671.
6Blanchard AR. Treatment of COPD exacerbations. Pharmacologic options and modification of risk factors [J]. Postgrad Med, 2002,111 (6) : 65-68.
10Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol[J]. Chest, 2002,122 ( 1 ) : 47-55.
2J C Bestall, E A Paul, R Garrod, et al. Usefulness of the Medical Research Council ( MRC ) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax, 1999, 54(7) :581 -586.
3National Heart, Lung and Blood Institute (NHLBI). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Updated 2007.
4Binks AP, Moosavi SH, Banzett RB, et al. "Tightness" sensation of asthma does not arise from the work of breathing. Am J Respir Crit Care Med,2002,165 ( 1 ) : 78 - 82.
5C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J, 2006,27 ( 5 ) :902 - 907.
6Armijo JA, Sanchez BM, Peralta FG, et al. Pharmacokinetics of an ultralong sustained-release theophylline formulation when given twice daily in elderly patients with chronic obstructive pulmonary disease : monitoring implications. Biopharm Drug Dispos, 2003,24 (4) :165 -171.
7[3]National Heart,Lung,and Blood Institute and World Health Organization.Global initiative for chronic obstructive lung disease:global strategy for diagnosis,management,and prevention of chronic obstructive pulmonary disease.2005 update.National Institutes of Health,Bethesda
8[4]Jenne J,Wyre-Rood FS,Stelts D,etal.Phamacokinetics of theophylline.Clin Phamacol Ther,1998,13(5):349
9[5]Iodice F,De-Michele F,Sena A,etal.Effetti ventilatoried emogasanalitical della somm in istrazione acute della doxofyllina in soggetti con BPCO.Respiratory Medicine,2001,8(6):219
10Barnes PJ. Theophylline: new perspectives for an old drug.Am J Respir Grit Care Med, 2003, 167(6):813-818
